Restricted accessOtherFirst published online 1999-09
Year 2000 guidelines for clinical practice of whole body hyperthermia combined with cytotoxic drugs from the University of Lübeck and the University of Wisconsin
Robins HI.Systemic Hyperthermia Oncological Working Group. 1st annual meeting, New York, NY, June 7-8, 1994. Oncology. 1995;52:260-263.
2.
Robins HI, Neville AJ, Cohen JD.Whole Body Hyperthermia. Biological and Clinical Aspects. Heidelberg, Germany: Springer-Verlag; 1992.
3.
Robins HI, Cohen JD, Schmitt CL, et al.Phase I clinical trial of carboplatin and 41.8°C whole body hyperthermia in cancer patients. J Clin Oncol. 1993;11:1787-1794.
4.
Wiedemann GJ, d’Oleire F, Knop E, et al.Ifosfamide and carboplatin combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res. 1994;54:5346-5350.
5.
Wiedemann GJ, Mentzel M, Katschinski DM, Gutsche S, Wagner T, and Robins HI.Ifosfamide, Carboplatin, and Etoposide (ICE) Combined with 41.8°C Whole-Body Hyperthermia (WBH) for Refractory Sarcoma. VII International Congress on Hyperthermic Oncology. 1996;1189-1189.
6.
Wiedemann GJ, Katschinski DM, Mentzel M, Gutsche S, Wagner T, Robins HI.Ifosfamide, carboplatin, and etoposide combined with 48°C whole-body hyperthermia (WBH) for refractory sarcoma. AACR. 1996;37:1189-1189. Abstract.
7.
Wiedemann GJ, Robins HI, Katschinski DM, et al.Klinische Studien zur Kombination von Ifosfamid, Carboplatin, and Etopo-side (ICE) mit Ganzkorperhyperthermie. Medizinische Klinik, 1996;91:279-283.
8.
Wiedemann GJ, Robins HI, Katschinski DM, et al.Systemic hyper-thermia and ICE chemotherapy for sarcoma patients: rationale and clinical status. Anticancer Res. 1997;17:2899-2902.
9.
Wiedemann GJ, Robins HI, Gutsche S, et al.Ifosfamide, carboplatin, and etoposide (ICE) combined with 41.8°C whole-body hyper-thermia in patients with refractory sarcoma. Eur J Cancer. 1996; 32A:888-892.
10.
Robins HI, Schmitt-Tiggelaar CL, Cohen JD, et al.A new technological approach to radiant heat whole body hyperthermia. Cancer Lett. 1994;79:137-145.
11.
Robins HI, Dennis WH, Neville AJ, et al.A non-toxic system for 41.8°C whole body hyperthermia: results of a phase I study using a radiant heat device. Cancer Res. 1985;45:3937-3940.
12.
Brauer L, Prieshof B, Wiedemann G, et al.Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. J Cancer Res Clin Oncol. 1998;124:549-554.
13.
Wiedemann GJ, Katschinski DM, Mentzel M, et al.Ifosfamide (IFO), carboplatin (CBDCA), and etoposide (VP-16) combined with Aquatherm induced 41.8°C whole-body hyperthermia (WBH) for refractory sarcoma. J Clin Oncol. 1996;14:1751-1751.
14.
Robins H, Rushing D, Kutz M, et al.Phase I clinical trial of melphalan (L-PAM) and 41.8°C whole body hyperthermia in cancer patients. J Clin Oncol. 1997;15:158-164.
15.
Robins HI, Longo WL, Steeves RA, et al.A pilot study of whole body hyperthermia and local irradiation for advanced non-small cell lung cancer confined to the thorax. Int J Radiat Oncol Biol Phys. 1988;15:427-431.
16.
Robins HI, Longo WL, Steeves RA, et al.Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B cell neoplasms: a report of two pilot clinical trials and laboratory investigations. Int J Radiat Oncol Biol Phys. 1990;18:909-920.
17.
Robins HI, Longo WL, Hugander A, et al.Whole body hyperthermia combined with total body irradiation and chemotherapy as a preparative regimen for allogenic bone marrow transplantation in a patient with Burkitt’s lymphoma. Cancer J. 1986;1:180-183.
18.
Robins HI, Katschinski DM, Longo W, et al.A pilot study of melphalan, tumor necrosis factor a, and 41.8°C whole body hyperthermia. Cancer Chemother Pharmacol. 1999;43:409-414.
19.
Robins HI, Sielaff KM, Storer B, Hawkins MJ, Borden EC.A phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer. Cancer Res. 1989;49:1609-1615.
20.
Robins HI, Longo WL, Lagoni RJ, et al.A phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Res. 1988;48:6587-6592.
21.
Rietbroek RC, Katschinski DM, Reijers MHE, et al.Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia. 1997;13: 525-533.
22.
Clark A, Robins HI, Vorphal JW, Yatvin MB.Structural changes in murine cancer associated with hyperthermia and lidocaine. Cancer Res. 1983;43:1716-1723.
23.
Robins HI, Grossman J, Davis TE, Dennis WH, Aubuchon JP.A preclinical trial of a radiant heat device for whole body hyperthermia using a porcine model. Cancer Res. 1983;43:2018-2022.
24.
Robins HI, Dennis WH, Slattery JS, Lange TA, Yatvin MB.Systemic lidocaine enhancement of hyperthermia-induced tumor regression in transplantable murine models. Cancer Res. 1983;43:3187-3191.
25.
Robins HI, Dennis WH, Martin PA, Sondel PM, Yatvin MB, Steeves RA.Potentiation of differential hyperthermic sensitivity of AKR leukemia and normal bone marrow cells by lidocaine or thiopental. Cancer. 1984;54:2831-2835.
26.
Robins HI, Dennis WH, Steeves RA, Sondel PM.A proposal for the addition of hyperthermia to treatment regimens for acute and chronic leukemia. J Clin Oncol. 1984;2:1050-1056.
27.
Robins HI, Kutz M, Wiedemann G, et al.Cytokine induction by 41.8°C whole body hyperthermia. Cancer Lett. 1995;97:195-201.
28.
d’Oleire F, Robins HI, Cohen JD, Schmitt CL, Spriggs D.Cytokine induction in humans by 41.8°C whole body hyperthermia. J Natl Cancer Inst. 1993;85:833-834.
29.
Katschinski DM, Wiedemann GJ, d’Oleire FR, Longo W, Robins HI.Whole body hyperthermia cytokine induction: a review and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. Cytokine Growth Factor Rev. In press.
30.
Woods JP, Schmitt-Tiggelaar CL, d’Oleire F, Rosenthal RC, Robins HI.Hematological effects of radiant heat-induced whole body hyperthermia on dogs. Can J Vet Res. 1996;60:75-78.
